Takeda Pharmaceutical Co Ltd

Company Snapshot
1-1, Nihonbashi-Honcho 2-Chome
Tokyo, 103-8668
Japan
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 49,095
https://www.takeda.com
Please select from the dropdown
Company Financials

2021
2022
2023
Gross Profit
$2,203,504,000,000
$2,462,160,000,000
$2,783,406,000,000
Operating Income
$338,311,000,000
$533,019,000,000
$553,106,000,000
Net Income
$376,005,000,000
$230,059,000,000
$317,017,000,000
2021
Gross Profit
$2,203,504,000,000
Operating Income
$338,311,000,000
Net Income
$376,005,000,000
2022
Gross Profit
$2,462,160,000,000
Operating Income
$533,019,000,000
Net Income
$230,059,000,000
2023
Gross Profit
$2,783,406,000,000
Operating Income
$553,106,000,000
Net Income
$317,017,000,000
The above data on Takeda Pharmaceutical Co Ltd came from annual proxy statements to the SEC. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov
Top Executives
Total Cash info
Equity info
Other info
Total Compensation
Top Executives
Total Compensation
Christophe Weber
Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U.S.A., Inc.
$572,000,000
$1,151,000,000
$0
$1,723,000,000
Christophe Weber
$1,723,000,000
Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U.S.A., Inc.
Andrew Plump
Director and President, Research and Development
$365,000,000
$564,000,000
$43,000,000
$972,000,000
Andrew Plump
$972,000,000
Director and President, Research and Development
Emiko Higashi
Independent Director
$24,000,000
$19,000,000
$0
$43,000,000
Emiko Higashi
$43,000,000
Independent Director
Koji Hatsukawa
Independent Director
$24,000,000
$19,000,000
$0
$43,000,000
Koji Hatsukawa
$43,000,000
Independent Director
Masami Iijima
Chairman of the Board
$24,000,000
$19,000,000
$0
$43,000,000
Masami Iijima
$43,000,000
Chairman of the Board
Takeda Pharmaceutical Co Ltd listed the above executives on its annual proxy statement to the SEC for the fiscal year of 2023. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov

The sum of all cash payments made to an individual for services during a given year. It is comprised of yearly Base Pay and Bonuses

To view more detailed proxy data including previous years contact our sales team.

Contact Us

The value of stock and option awards plus long term incentives granted.

To view more detailed proxy data including previous years contact our sales team.

Contact Us

This covers all compensation that don't fit in any of these other standard categories

To view more detailed proxy data including previous years contact our sales team.

Contact Us